Interleukin-17: A Promoter in Colorectal Cancer Progression

Table 2

Expression of IL-17 in CRC patients.

Sample type	Sample size	Findings	References
Serum and tissue	74 CRC tissues and paired normal mucosa, 61 CRC serum samples, and 78 healthy controls	No significant difference is observed.	[59]
Serum and tissue	59 CRC tissues, 40 CRC serum samples, and 37 healthy controls	IL-17 acts as a valuable tumor marker in CRC patients.	[56]
Tissue	12 CRC patients	Hypoxia induce the expression of IL-17 in Foxp3^+ Tregs, which drive cancer cells to be cancer-initiating cells.	[51]
Tissue	125 CRC tissues and 3 normal tissues	IL-17 gene expression level is higher in tumor tissues compared to normal mucosa.	[60]
Tissue	52 CRC patients	IL-17 expression is negatively correlated with OS of CRC patients.	[52]
Tissue	22 CRC patients	Tumor-infiltrating Foxp3^+ IL-17^+T cells suppress tumor-specificCD8^+T cells response via IL-17.	[49]
Serum and tissue	9 ulcerative colitis-associated CRC tissues	IL-17^+Foxp3^+CD4^+T cells are selectively accumulated in the colitis-associated CRC niche.	[61]
Tissue	50 colorectal adenomas tissues, 50 CRC tissues, and 15 healthy controls	IL-17 level is associated with the severity of dysplastic degree.	[58]
Tissue	23 CRC patients	Tumor-infiltrating TH17 cells and Bv8-expressing neutrophils are associated with poor outcome in CRC.	[50]